---
schema_version: "secwatch.filing_event.v1"
accession: "0001005286-25-000052"
form_type: "8-K"
ticker: "LFCR"
cik: "0001005286"
company_name: "LIFECORE BIOMEDICAL, INC. DE"
filed_at: "2025-04-03T23:59:59+00:00"
generated_at: "2026-05-23T22:09:57.202815+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lifecore Biomedical reports Q3 FY2025 revenue $35.2M, net loss $14.8M, sells unused filler for $17M

## Summary
- Revenue $35.2M, down 2% YoY; CDMO revenue declined $1.5M, partially offset by HA manufacturing growth of $1.0M.
- Net loss of $14.8M ($0.47 diluted loss per share) vs prior-year net income of $15.6M including $21M non-cash debt derivative gain.
- Adjusted EBITDA $5.7M, down from $6.4M YoY; gross profit fell to $9.8M from $11.9M.
- Sold unused high-speed isolator filler for $17M; $7M received at closing, remainder over 18 months. Signed multiple new development agreements.

## SEC filing metadata
- accession: 0001005286-25-000052
- form_type: 8-K
- ticker: LFCR
- cik: 0001005286
- company_name: LIFECORE BIOMEDICAL, INC. DE
- filed_at: 2025-04-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1005286/000100528625000052/0001005286-25-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1005286/000100528625000052/lndc-20250403.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001005286-25-000052
- JSON: https://secwatch.observer/filing/0001005286-25-000052.json
- Plain text: https://secwatch.observer/filing/0001005286-25-000052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.